A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
REGULATORY
Gist of FY2025 Drug Price Revision
The FY2025 NHI price revision will be implemented as follows based on the “basic policy for drastic drug pricing reform” (agreed upon by the then chief cabinet secretary, finance minister, health minister, and economic revitalization minister on December 20, 2016)…
To read the full story
Related Article
- MHLW Official Reveals Rationales Behind Off-Year Decision, Says PMP Return Is Reasonable
January 8, 2025
- Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
December 26, 2024
- Off-Year Price Revision to Hit 53% of Listed Drugs in 2025, Down from 69%
December 23, 2024
- Three Ministers Agree on Off-Year Drug Price Revision in FY2025
December 20, 2024
- Japan Set to Settle Off-Year Debate with “x1.0” Threshold for PMP Meds/Generics, “x0.5” for LLPs
December 20, 2024
- (Update) Average NHI-Market Price Gap Narrows to 5.2% to Hit Record Low
December 4, 2024
REGULATORY
- MHLW Eyes 2 Biz Models as It Pushes Generic Industry Shakeup: Minister
January 23, 2025
- Draft Bill to Amend PMD Act Up for LDP Review on Jan. 27
January 23, 2025
- How’s Drug Discovery Fund Different from AMED? LDP Member Says It’s Too Early to Submit Legislation
January 22, 2025
- Astellas’ Xtandi on 2nd Drug List Up for IRA Price Negotiations
January 21, 2025
- Lixiana Label Expansion on Agenda for MHLW Panel Session on Jan. 31
January 20, 2025
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…